EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
|
EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Preliminary Results
Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
17-Jan-2023 / 12:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) is expected to achieve a Group net profit of roughly EUR 30 million and Group sales of around EUR 225 million for the 2022 financial year. The result is thus expected to be around 10% higher than the figures forecasted in July 2022 of around EUR 27 million for Group net profit and around EUR 200 million for Group sales.
The audited full annual financial statements for the FY 2022 are scheduled to be published on 30 March 2023.
For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
17-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
Eckert & Ziegler Strahlen- und Medizintechnik AG |
|
Robert-Rössle-Str.10 |
|
13125 Berlin |
|
Germany |
| Phone: |
+49 30 941084-138 |
| Fax: |
+49 30 941084-112 |
| E-mail: |
[email protected] |
| Internet: |
www.ezag.de |
| ISIN: |
DE0005659700 |
| WKN: |
565970 |
| Indices: |
SDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1536993 |
| |
| End of Announcement |
EQS News Service |
1536993 17-Jan-2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
138,63 |
168,71 |
178,49 |
176,14 |
180,44 |
222,26 |
246,09 |
| EBITDA1,2 |
26,62 |
32,14 |
43,13 |
44,64 |
57,04 |
55,52 |
58,83 |
| EBITDA-Marge3 |
19,20 |
19,05 |
24,16 |
25,34 |
31,61 |
24,98 |
|
| EBIT1,4 |
17,97 |
23,39 |
32,06 |
33,69 |
47,45 |
44,54 |
45,45 |
| EBIT-Marge5 |
12,96 |
13,86 |
17,96 |
19,13 |
26,30 |
20,04 |
18,47 |
| Jahresüberschuss1 |
15,12 |
16,89 |
22,48 |
23,11 |
34,66 |
29,75 |
26,77 |
| Netto-Marge6 |
10,91 |
10,01 |
12,59 |
13,12 |
19,21 |
13,39 |
10,88 |
| Cashflow1,7 |
26,83 |
21,21 |
40,43 |
36,79 |
33,86 |
34,30 |
47,40 |
| Ergebnis je Aktie8 |
0,70 |
0,78 |
1,07 |
1,11 |
1,66 |
1,41 |
1,26 |
| Dividende8 |
0,20 |
0,30 |
0,42 |
0,45 |
0,50 |
0,50 |
0,17 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Mazars
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Eckert & Ziegler |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 565970 |
36,040 |
Halten |
763,04 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 22,53 |
26,22 |
0,87 |
39,65 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 3,45 |
16,10 |
3,10 |
12,45 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,50 |
0,05 |
0,14 |
28.05.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 14.05.2024 |
09.08.2024 |
14.11.2024 |
22.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -8,44% |
-2,95% |
-12,74% |
-22,89% |
|
|
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700